Short Interest in Sosei Group Co. (OTCMKTS:SOLTF) Drops By 17.2%

Sosei Group Co. (OTCMKTS:SOLTF) saw a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,757,400 shares, a drop of 17.2% from the July 31st total of 2,121,800 shares. Based on an average daily volume of 300 shares, the short-interest ratio is presently 5,858.0 days.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on SOLTF shares. Citigroup lowered Sosei Group from a “buy” rating to a “sell” rating in a research note on Wednesday, June 28th. Jefferies Financial Group lowered Sosei Group from a “buy” rating to an “underperform” rating in a research note on Tuesday, June 27th.

Sosei Group Stock Down 0.3 %

Shares of OTCMKTS:SOLTF opened at $11.37 on Monday. Sosei Group has a 1 year low of $10.01 and a 1 year high of $22.78. The business’s 50 day moving average price is $12.59 and its 200-day moving average price is $16.77.

Sosei Group Company Profile

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia.